Notice: This company has been marked as potentially delisted and may not be actively trading. Neurotrope (NTRP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsEarningsHeadlinesShort InterestTrends NTRP vs. HEPA, GHSI, YGMZ, AZRX, ACST, SNSS, BKNG, EXPE, XPO, and MMYTShould you be buying Neurotrope stock or one of its competitors? The main competitors of Neurotrope include Hepion Pharmaceuticals (HEPA), Guardion Health Sciences (GHSI), MingZhu Logistics (YGMZ), AzurRx BioPharma (AZRX), Acasti Pharma (ACST), Sunesis Pharmaceuticals (SNSS), Booking (BKNG), Expedia Group (EXPE), XPO (XPO), and MakeMyTrip (MMYT). Neurotrope vs. Hepion Pharmaceuticals Guardion Health Sciences MingZhu Logistics AzurRx BioPharma Acasti Pharma Sunesis Pharmaceuticals Booking Expedia Group XPO MakeMyTrip Hepion Pharmaceuticals (NASDAQ:HEPA) and Neurotrope (NASDAQ:NTRP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends, community ranking and profitability. Is HEPA or NTRP more profitable? Neurotrope's return on equity of -286.56% beat Hepion Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Hepion PharmaceuticalsN/A -408.98% -174.30% Neurotrope N/A -286.56%-100.34% Which has more risk and volatility, HEPA or NTRP? Hepion Pharmaceuticals has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500. Comparatively, Neurotrope has a beta of 1.67, indicating that its share price is 67% more volatile than the S&P 500. Do institutionals & insiders have more ownership in HEPA or NTRP? 17.2% of Hepion Pharmaceuticals shares are held by institutional investors. Comparatively, 3.8% of Neurotrope shares are held by institutional investors. 2.0% of Hepion Pharmaceuticals shares are held by company insiders. Comparatively, 9.7% of Neurotrope shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has higher valuation and earnings, HEPA or NTRP? Neurotrope has higher revenue and earnings than Hepion Pharmaceuticals. Neurotrope is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHepion PharmaceuticalsN/AN/A-$48.93M-$6.40-0.10Neurotrope$630K4.21-$15.58M-$10.97-0.17 Does the media favor HEPA or NTRP? In the previous week, Hepion Pharmaceuticals had 3 more articles in the media than Neurotrope. MarketBeat recorded 4 mentions for Hepion Pharmaceuticals and 1 mentions for Neurotrope. Hepion Pharmaceuticals' average media sentiment score of 0.22 beat Neurotrope's score of 0.00 indicating that Hepion Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Hepion Pharmaceuticals Neutral Neurotrope Neutral Does the MarketBeat Community favor HEPA or NTRP? Neurotrope received 159 more outperform votes than Hepion Pharmaceuticals when rated by MarketBeat users. However, 67.74% of users gave Hepion Pharmaceuticals an outperform vote while only 63.38% of users gave Neurotrope an outperform vote. CompanyUnderperformOutperformHepion PharmaceuticalsOutperform Votes2167.74% Underperform Votes1032.26% NeurotropeOutperform Votes18063.38% Underperform Votes10436.62% Do analysts recommend HEPA or NTRP? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hepion Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Neurotrope 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryHepion Pharmaceuticals beats Neurotrope on 8 of the 14 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Neurotrope News Delivered to You Automatically Sign up to receive the latest news and ratings for NTRP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NTRP vs. The Competition Export to ExcelMetricNeurotropeTransportation services IndustryDiscretionary SectorNASDAQ ExchangeMarket Cap$2.66M$12.08B$8.07B$8.93BDividend YieldN/A8.09%2.69%4.02%P/E Ratio-0.1717.0619.1418.07Price / Sales4.213.807.5375.10Price / CashN/A28.4433.1536.30Price / Book0.564.044.136.01Net Income-$15.58M$368.31M$261.16M$224.44M Neurotrope Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NTRPNeurotrope0.3007 of 5 stars$1.87+10.0%N/AN/A$2.66M$630,000.00-0.175Gap UpHEPAHepion Pharmaceuticals0.5025 of 5 stars$0.63-6.0%N/A-79.4%$3.63MN/A-0.1020Upcoming EarningsShort Interest ↑News CoverageGap DownGHSIGuardion Health Sciences1.655 of 5 stars$3.22-2.1%N/A-46.4%$4.35M$12.25M0.6610Gap DownYGMZMingZhu Logistics0.5966 of 5 stars$1.24-2.4%N/A-71.3%$5.93M$89.00M0.00180Short Interest ↑AZRXAzurRx BioPharmaN/A$0.64-7.3%N/A+130.3%$5.94MN/A-0.0612ACSTAcasti Pharma2.0604 of 5 stars$3.37-0.9%$10.00+196.7%+51.5%$31.68MN/A-2.9632SNSSSunesis PharmaceuticalsN/AN/AN/AN/A$96.26M$2.07M-2.8124Analyst ForecastGap UpBKNGBooking4.6021 of 5 stars$5,022.92-0.8%$4,749.83-5.4%+63.4%$166.24B$23.05B34.0823,600Short Interest ↑EXPEExpedia Group4.8877 of 5 stars$182.00-1.3%$161.62-11.2%+53.4%$23.69B$13.39B23.4217,100Analyst DowngradeShort Interest ↓XPOXPO3.6103 of 5 stars$151.42-2.4%$139.88-7.6%+82.2%$17.63B$8.09B49.0038,000Analyst ForecastShort Interest ↑MMYTMakeMyTrip2.2908 of 5 stars$104.20-2.5%$98.00-6.0%+150.6%$11.44B$782.52M56.944,576Analyst Upgrade Related Companies and Tools Related Companies Hepion Pharmaceuticals Alternatives Guardion Health Sciences Alternatives MingZhu Logistics Alternatives AzurRx BioPharma Alternatives Acasti Pharma Alternatives Sunesis Pharmaceuticals Alternatives Booking Alternatives Expedia Group Alternatives XPO Alternatives MakeMyTrip Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NTRP) was last updated on 11/13/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredYou just voted for a financial crisisI’d like to share with you my #1 high-conviction stock to buy before Inauguration Day… and details on the asse...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurotrope, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurotrope With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
